Introduction
============

In 2006, approximately 153,100 new cases of cancer and 70,400 deaths from cancer will occur in Canada ([@b5-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Bone metastases are a frequent complication of cancer, and half of the individuals who died of cancer have bone metastates ([@b20-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Breast and prostate carcinomas are the most common to develop metastases to bone, with an incidence of 75% and 68%, respectively ([@b17-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). In addition, lung, thyroid, and renal carcinoma metastasize to bone in approximately 40% of cases ([@b20-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). With advances in effective systemic treatment and supportive care, the duration of survival of patients with bone metastases has improved substantially. Certain subsets of patients with bone metastases (eg, breast and prostate cancer with predominately bone or bone-only metastases) have life expectancies that range from two to five years. The five-year survival rate of breast cancer patients with either bone or bone-only metastases can be as high as 45%, and those with bone-only metastases have a median survival of 52 months ([@b17-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]; [@b24-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis], [@b25-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Thus, successful management of bone metastases during these years is essential for reducing skeletal complications and for maximizing patient quality of life. The following reasons demonstrate an urgent need to reassess the management strategies in patients with bone metastases ([@b3-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]; [@b1-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]; [@b16-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]; [@b6-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]):

1.  Pain arising from bone metastases is the most common symptom requiring radiotherapy treatment in cancer patients;

2.  The symptoms of bone metastases are often severe and develop earlier in the clinical course of patients with cancer than symptoms due to either liver or lung metastases;

3.  Complications of skeletal metastases are common and can seriously impair patient quality of life and function. Pain and impaired mobility occur in 65%--75% of patients with bone metastases; fractures of weight-bearing long bones occur in 10%--20%; hypercalcemia occurs in 10%--15%; and spinal cord or nerve root compression occurs in 5%;

4.  Increasing incidence of bone metastases and longer survival duration of patients with bone metastases has been observed and;

5.  The care of this group of patients has been poorly integrated and coordinated.

Fifty to 75% of patients with bone metastases suffer from severe pain ([@b8-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). As reflected in a consensus statement from a National Cancer Institute workshop, the under-treatment of cancer pain is a serious and often neglected public health problem ([@b11-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Treatment for symptomatic bone metastases often involves multiple care providers including medical and radiation oncologists, pain specialists, surgeons, and other health care professionals. Clinical trials in various disciplines addressing the optimal management of bone metastases are under way and treatment options for bone metastases have been expanding as reflected in the latest clinical trials testing the newer generations of bisphosphonates ([@b23-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]) and increased use of orthopedic surgery.

Radiotherapy and orthopedic stabilization are effective palliative measures for bone metastases. Singer commented that "bone pain from mechanical effects often necessitates long term treatment with strong analgesics" ([@b21-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). In response, [@b13-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis] stated that the most effective solution for mechanical pain is surgery. [@b10-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis] reported that surgical stabilization of such lesions often gives the patient total pain relief and may obviate the need for analgesics. Although such therapies are effective in alleviating pain, specialists who deliver the treatments often work independently, leading to the lack of a coordinated treatment. This is evident in the review by [@b15-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis] of 269 women with breast cancer who had developed bone metastases. Eighty- two episodes of structurally significant bone destruction in 47 women were identified. The researchers concluded that clinical review by an orthopaedic surgeon would have been appropriate in 89% of the episodes, but such a review was sought in only 46%. Surgery would have been feasible for 65% of the episodes, but was carried out in only 31%. Bracing would have been appropriate in 40% of episodes, but was provided in only 18%.

To date, only one published report exists that describes an integrated clinic model for the multidisciplinary management of bone metastases. The clinic was developed at the University of Texas M.D. Anderson Cancer Centre to provide an effective and comprehensive management of bony metastases ([@b14-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). In total, presenting symptoms and the extent of disease of 108 patients were retrospectively evaluated. Presenting symptoms were evaluated with the Wisconsin Brief Pain Inventory. Patients were assessed by staff physicians from diagnostic radiology, nuclear medicine, pain and symptom management, physical medicine and rehabilitation, orthopedic surgery, medical oncology and radiotherapy. The assessment included a review of past therapies, evaluation of current treatment options and consideration of underlying medical conditions. [@b12-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis] suggested that the use of multidisciplinary coordination of care can help to overcome many practical difficulties and address specific problems in the management of metastatic disease in symptomatic patients.

The Division of Orthopedics at Sunnybrook Health Sciences Centre and the Rapid Response Radiotherapy Program at Toronto Sunnybrook Regional Cancer Centre initiated a first-of-its-kind clinic, the Bone Metastases Clinic, at the Toronto-Sunnybrook Regional Cancer Centre in January 1999. The clinic aims to provide a coordinated multidisciplinary approach to the care of cancer patients with bone metastases. This multidisciplinary service will also save the time and effort that a patient would otherwise expend during separate, sequential visits to various specialists for consultation.

This paper is to report our experience at the Bone Metastases Clinic since its inception in 1999.

Methods
=======

The BMC is managed by a team of specialists in various disciplines: interventional radiology, nursing, orthopedic surgery, pain and palliative medicine, radiation oncology, and radiation therapy. The clinic sees patients every second and fourth Friday of each month.

A prospective database has been set up for patients referred for joint consultation at BMC since January 1999. The referral required a pathological diagnosis of cancer and documentation of bone metastatic disease either by pathological confirmation, clinical examination or imaging studies. Patients were enrolled into the database if they were able to speak English, give verbal consent and respond to questions that assessed their symptoms. Patients were excluded from the database if they were confused, refused, or were unable to complete the symptom assessment.

During the initial consultation, patient demographics, cancer history, disease status and symptom profiles were collected. Patients were asked to rate their symptom distress using the Edmonton Symptom Assessment Scale (ESAS) with an 11 point categorical scale (0--10, 0 = lack of symptom, 10 = worst possible symptom). The scale evaluates nine symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, sense of well-being, and shortness of breath). Analgesic consumption, site(s) of bone metastases and the risk of fractures at the first visit were assessed and recorded. The functional status of the patient was scored as follows: normal with pain free use of the extremity and spine; normal use with pain; significant limited use (eg, use of prosthesis, walker, cane, crutches, and sling); and nonfunctional extremity/ spine (wheelchair bound, bedridden).

Patients were assessed by an orthopaedic surgeon, a radiation oncologist and a pain specialist at the consultation. The team then made a joint recommendation based on their assessments. Nursing and radiation therapy support was also provided. If the patient was a candidate for percutaneous vertebroplasty, an interventional radiologist was consulted.

Results
=======

Patient characteristics and baseline symptom distress
-----------------------------------------------------

From January 1999 to February 2005, a total of 272 patients with bone metastases were referred to the BMC. One hundred and seven patients were female (54%) and 125 were male (46%). Their median age was 65 years and the three most common primary sites were breast (31%), lung (21%) and prostate (11%). The median KPS score at consultation was 60 (range 30--90). The majority of patients (74%) arrived from their home, and only 9% arrived from a hospital or a hospice facility. About 10% of the patients had significant weight loss, which was defined as ≥10% over the last 6 months ([Table 1](#t1-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"}). A total of 354 reasons for referral were recorded, where almost a third (28%) of patients had 2 or more reasons of referral. The top three reasons for referral were bone pain (42%), bone metastases (21%) and high risk for pathological fracture (12%). Patients identified the spine (41%), pelvis and hips (26%), lower limbs (17%), and upper limbs (13%) as the most painful bony sites ([Table 2](#t2-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"}). [Table 3](#t3-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"} summarizes the ESAS scores at initial consultation. Fatigue and the sense of wellbeing were the two most severe symptoms that patients experienced (median of 4 and 3.5, respectively). Pain, depression and anxiety were also bothersome, with a median score of 3.

Orthopaedic assessment
----------------------

At consultation, the staff orthopaedic surgeon's assessment was recorded. The functional status of the affected extremity/ spine, the presence or risk of fractures and the severity of the risk was recorded. The report was completed only about 50% of the time (n = 137). The records show that 35% of the patients reported significant limited use of their affected extremity or spine (as evident in the use of prosthesis, walker, cane, crutches and sling), 25% reported normal use with pain, 15% reported complete nonfunctional use (wheelchair-bound or bedridden) and 14% had normal and pain free use ([Table 4](#t4-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"}).

When assessed for the presence or risk of fractures, it was found that 47% of patients were at a high risk of fractures, 34% were at low risk and 12% presented with a fracture at consultation ([Table 5](#t5-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"}). Of the 65 patients in high risk, 34 (52%) of them had a high risk of fractures at the extremities, where 22 of them (65%) presented with a lytic lesion that was \>2.5 cm in size at their extremities. Thirty patients (46%) were classified to have a high risk of fracture at the spine because of mechanical instability (16/30), spinal cord compression (12/30), cauda equina syndrome or more than two nerve root deficits (2/30).

Case dispositions and recommendations
-------------------------------------

After thorough examination and evaluation of a patient's symptoms, the BMC team discussed to suggest the best course of action. Of the 272 patients who received consultation, 40% received palliative radiotherapy, 19% received interventional surgery, 7% were referred to other support services such as physiotherapy, and 7% had further investigation or imaging completed ([Table 6](#t6-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table"}).

Discussions
===========

Optimal management of structurally significant bony metastases often requires an overall effort to restore and maintain function, as well as relieve cancer-related pain. Pain is the most frequent symptom of bone metastases. It develops slowly and becomes progressively more severe. In the early stages, pain can mostly be controlled with acetaminophen, anti-inflammatory agents and opiates. Despite being on a stable opioid treatment regimen, incident pain (a transitory flare of pain upon movement) is a common compliant among patients with bone metastases ([@b19-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). This type of pain restricts patients from normal activities and interferes with their ability to function.

When pain becomes progressively worst and patients fail to respond to drug therapy, alternative therapies must be considered. For the majority of patients with bone metastases, radiotherapy provides excellent palliation for localized bone pain. In 66% of patients, radiotherapy provided partial pain relief after a median time of 3 to 4 weeks ([@b14-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). However, patients may also experience episodes of an intensification of pain (pain flare) shortly after radiotherapy. About 14% of the patients receiving single dose of radiation experience pain flare on both day one and day two ([@b7-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Thus, modifications to the patient's analgesic regimen are necessary to control symptoms both during and after radiotherapy. However, the pain relieving effect of radiotherapy is not permanent. A median time to pain progression is 5 to 6 months following radiotherapy ([@b22-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]), and about 40% of patients experience an increase in pain after one year ([@b4-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). Retreatment is often also required when the effects of radiotherapy wears off. In a large RCT ([@b22-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]), 16% of all patients required re-treatment. The rate of retreatment was significantly more pronounced in patients who previously received a single fraction than those who received multiple fractions regimens (25% vs 7%). Other than palliating pain, radiotherapy can also be used to prevent a pathologic fracture and treat neurological complications from spinal cord compression ([@b2-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). However, when radiotherapy is inadequate to palliate pain or manage such complications, surgery may be indicated.

> "Orthopedic surgery is often prescribed to palliate bone pain and restore function. Patients can benefit from procedures such as intramedullary nailing, or prophylactic internal fixation when the risk of pathological fracture is significant. To prevent further tumor growth and bone loss, radiotherapy should follow surgery. Newer minimally invasive procedures such as percutaneous vertebroplasty and kyphoplasty are also highly effective in treating painful vertebral compressive fractures and preventing future vertebral collapse."
>
> ---
>
> (
>
> Forney et al 2003
>
> )

The complicated disease trajectory in patients with bone metastases necessitates a multidisciplinary effort between various specialties to provide symptom relief, maintain or restore function, and improve patients' quality of life. Effective and comprehensive management approaches are imperative to ensure patients receive effective symptom and pain control and are assessed for: i) the risk of other complications that require emergent interventions and ii) the need for other therapies and support service. The Toronto Sunnybrook Regional Cancer Centre Bone Metastases Clinic demonstrates that the integration of services allows for more streamlined care and eliminates the inconvenience of separate visits to various specialists for consultation. With one visit, the patient benefits from a multidisciplinary evaluation that assesses the appropriate intervention to palliate the presenting symptoms ([Figure 1](#f1-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="fig"}). Patients can also benefit from an additional resource: a 40-page educational binder titled "Helping You to Help Yourself " [@b18-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]). The resource book was developed specifically for patients with bone metastases by the BMC team and the nurse coordinator of the clinic. Contents include treatment information, coping strategies, tips on effective management of pain and fatigue, community resources, bone metastases diagnosis information and relevant case studies ([@b18-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis]).

One limitation of the study is the incomplete data on symptom distress measured by the ESAS and recorded on orthopaedic assessments. Modifications to patients' analgesic regimen should also be carefully recorded. Future studies should investigate improved methods of collecting the information, examining quality of life measures, patient satisfaction and the cost-effectiveness of the clinic.
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###### 

Patient characteristics (n = 272)

  ------------------------------------------ -------------
  Sex                                        
   Male                                      147 (54%)
   Female                                    125 (46%)
  Age (years)                                
   Median (range)                            65 (28--95)
  Primary cancer site                        
   Breast                                    84 (31%)
   Lung                                      56 (21%)
   Prostate                                  30 (11%)
   Multiple Myeloma                          21 (8%)
   Kidney                                    20 (7%)
   Unknown                                   21 (7%)
   Gastrointestinal                          16 (6%)
   Others                                    24 (9%)
  Weight loss \>10% over the last 6 months   22 (10%)
  Karnofsky performance score                
   Median (range)                            60 (30--90)
  Painful bony sites                         
   Spine                                     111 (41%)
   Pelvis/Hips                               70 (26%)
   Lower limbs                               45 (17%)
   Upper limbs                               35 (13%)
   Trunk                                     8 (3%)
   Others                                    3 (1%)
  Patient arrived from                       
   Home                                      200 (74%)
   Hospital/Hospice                          24 (9%)
   Other                                     9 (3%)
   Unknown                                   39 (14%)
  ------------------------------------------ -------------

###### 

Reason(s) for referral[\*](#tfn1-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table-fn"}

  ------------------------------------- -----------
  Bone pain                             147 (42%)
  Bone metastases                       76 (21%)
  High risk for pathological fracture   41 (12%)
  Pathological fracture                 34 (10%)
  Spinal cord compression               20 (5%)
  Other pain                            16 (5%)
  Others                                20 (6%)
  ------------------------------------- -----------

**Note:** 354 reasons in total for n = 272.

###### 

Symptom distress according to the Edmonton symptom assessment scale

  Symptom               N     Mean   Standard deviation   Median   Range
  --------------------- ----- ------ -------------------- -------- -------
  Pain                  100   3.88   3.31                 3.0      0--10
  Fatigue               90    4.50   2.72                 4.0      0--10
  Nausea                91    1.09   1.88                 0.0      0--9
  Depression            83    2.75   2.57                 3.0      0--10
  Anxiety               87    3.33   2.77                 3.0      0--10
  Drowsiness            88    2.50   2.60                 2.0      0--10
  Appetite              90    3.28   3.26                 2.5      0--10
  Sense of well-being   86    3.95   2.59                 3.5      0--10
  Shortness of breath   90    1.86   2.36                 1.0      0--9

**Notes:** 0, lack of symptom; 10, worst possible symptom.

###### 

Functional status of extremity/spine (n = 137)

  Status                    
  ------------------------- ----------
  Significant limited use   48 (35%)
  Normal use with pain      34 (25%)
  Nonfunctional             20 (15%)
  Normal, pain-free use     19 (14%)
  Unknown                   16 (12%)

###### 

Presence of bone metastasis fractures/risk of fracture (n = 137)

  --------------------------------------------------- ----------
  Presence of fracture                                
   Pathological                                       14 (10%)
   Wedge                                              3 (2%)
  Total presence of fracture:                         17 (12%)
   Low risk                                           46 (34%)
   High risk                                          
  Extremities: 50%--74% cortex involved               5 (4%)
   ≥75% cortex involved                               6 (4%)
   Lytic lesion 2.5 to 5 cm in size                   11 (8%)
   Lytic lesion ≥ 5 cm in size                        5 (4%)
   Subtrochanteric region of femur                    7 (5%)
  Spine: Mechanical instability                       16 (12%)
   Cauda equine syndrome OR ≥ 2 nerve root deficits   2 (1%)
   Spinal cord compression                            12 (9%)
   No reason:                                         1 (1%)
  Total high risk                                     65 (47%)
  None                                                9 (7%)
  --------------------------------------------------- ----------

###### 

Case disposition and treatment recommendations (n = 280[\*](#tfn3-jpr_4573_noxious_counterirritation_in_patients_with_advanced_osteoarthritis){ref-type="table-fn"})

  ----------------------------------- -----------
  Radiotherapy                        108 (40%)
  Surgery                             53 (19%)
  Other support services              19 (7%)
  Further investigation and imaging   18 (7%)
  No action                           69 (25%)
  Others                              13 (4%)
  ----------------------------------- -----------

**Notes:** 4 patients received two treatment recommendations.
